Celebrating twenty years
By Jennifer Newton2017-08-02T15:39:00
Source: © Shutterstock
Whistleblower case relating to cancer prescriptions
US biotech firm Celgene has agreed to pay $280 million (£211 million) to settle a lawsuit over the company promoting its drugs Thalomid and Revlimid for off-label uses.